Inventiva S.A. — Form 6-K Summary
Business Context and Reporting Period
Inventiva S.A., a France-based clinical-stage biopharmaceutical company, filed this Form 6-K for May 2022. The filing reports entry into a finance contract with the European Investment Bank on May 16, 2022. Inventiva develops drug candidates, including lanifibranor for non-alcoholic steatohepatitis and cedirogant, which is being developed by AbbVie.
Financial Position and Key Metrics
- Potential financing: Up to €50 million under the EIB Finance Contract, divided into two €25 million tranches.
- Interest: 8% per annum on the first tranche and 7% per annum on the second tranche, with interest capitalized annually beginning on the first anniversary of disbursement.
- Repayment: Each tranche is repayable in a single installment, with maturity no later than four years after disbursement of the first tranche and three years after disbursement of the second tranche.
- Revenue and profitability: The filing provides no current-period revenue, profit, cash-flow, margin, debt-balance or liquidity figures. It states that Inventiva has no approved products, no historical product revenues, and has incurred significant losses since inception.
Material Changes and Financing Conditions
The material event is the execution of the EIB financing agreement. Funding is conditional and is not guaranteed to be received.
- The first €25 million tranche requires, among other conditions, a warrant subscription agreement and at least €18 million received after the contract date through equity issuances or upfront or milestone payments.
- The second tranche requires full drawdown of the first tranche, cumulative qualifying funding of at least €70 million, and either an out-licensing, partnership or royalty transaction with at least €10 million of upfront consideration or initiation of AbbVie’s Phase III cedirogant trial.
- The second tranche also requires evidence of at least 850 patients enrolled, or 650 patients enrolled and 300 sites activated, globally in Inventiva’s Phase III lanifibranor trial.
- Undisbursed amounts will be cancelled if not drawn within 36 months after execution of the contract.
Warrants, Risks and Outlook
As a condition to each tranche, Inventiva agreed to issue warrants to EIB. The number of warrants will depend on qualifying funding received and applicable share-price measures. Each warrant is expected to entitle EIB to one Inventiva share, with an exercise price equal to 95% of the volume-weighted average trading price over an agreed period. The warrants may be exercisable for up to 12 years following specified trigger events, subject to the definitive subscription agreement and other conditions.
Inventiva may prepay the financing subject to fees ranging from 6% in the first year after disbursement to 2% after the third year. EIB may demand accelerated repayment and/or cancel undisbursed tranches upon specified events of default, including payment defaults, misleading information, other financial defaults, insolvency-related events, or cessation or substantial reorganization of the business.
Management’s forward-looking statements include expectations regarding financing, strategic transactions, milestone payments, royalties, clinical development and product sales. Key risks include failure to satisfy financing conditions, inability to raise additional capital, clinical-trial delays or failures, lack of regulatory approval, patient enrollment challenges, dependence on AbbVie’s development activities, and potential effects of COVID-19 and geopolitical events including the Russia-Ukraine conflict.
Investor Verification Checklist
- Verify whether the EIB warrant subscription agreement was executed and whether either financing tranche was actually disbursed.
- Confirm Inventiva’s cash balance, cash runway, outstanding debt and subsequent financing activity in later filings.
- Track achievement of the €18 million and €70 million funding thresholds and the conditions tied to AbbVie’s cedirogant program.
- Monitor enrollment and site activation in the Phase III lanifibranor trial.
- Review the definitive Finance Contract and warrant terms, including potential dilution, maturity, prepayment and default provisions.